Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Jean-Luc Re Canon"'
Autor:
Severine Guiu Lahaye, Judith Balmana Gelpi, Ludovic Gauthier, Frédéric Bigot, Anthony Goncalves, Jean-Sebastien Frenel, Thomas Bachelot, Florence Dalenc, Audrey Mailliez, Camille Chakiba, Dominique Genet, Nathalie Dohollou, Isabelle Desmoulins, Jean-Luc Re Canon, Clara Guyonneau, Adrien Buisson, Louise-Marie Chevalier, Suzette Delaloge, Philippe Follana
Publikováno v:
Journal of Clinical Oncology. 40:TPS1116-TPS1116
TPS1116 Background: PARP inhibitors have documented clinical activity in patients with HER2 negative breast cancer (BC) and a germline pathogenic variant (PV) in BRCA1 or BRCA2. Defects in other genes involved in homologous recombination DNA repair (
Autor:
Edith Borcoman, Hannelore Denys, Jean-Luc Re Canon, Nuria Kotecki, Vincent Vanhaudenarde, Marianne Paesmans, Claire Cheymol, Stéphane Holbrechts, Florian Clatot, Lore Decoster, Andrea Gombos, C. Duhem, Nadège Kindt, Maria Alice Franzoi, Ahmad Awada, Philippe Barthélémy, Jean-Pierre Delord, François Duhoux, Anthony Gonçalves
Publikováno v:
Journal of Clinical Oncology
Journal of Clinical Oncology, 2021, 39 (15_suppl), pp.TPS2066-TPS2066. ⟨10.1200/JCO.2021.39.15_suppl.TPS2066⟩
Journal of Clinical Oncology, 2021, 39 (15_suppl), pp.TPS2066-TPS2066. ⟨10.1200/JCO.2021.39.15_suppl.TPS2066⟩
TPS2066 Background: Better knowledge on the evolving epidemiology and biology of CNS metastases are key elements for the development of new treatment strategies and identification of promising therapeutic targets. A multidisciplinary Brain Metastases
Autor:
Lulu Cheng, Aung Naing, John Bridgewater, Olumide B. Gbolahan, May Thet Cho, Kyriakos P. Papadopoulos, Jean-Luc Re Canon, Sonia Ioannidis, Milind Javle, Christiane Jungels, Fiona C Thistlethwaite, Sven Gogov
Publikováno v:
Journal of Clinical Oncology. 39:311-311
311 Background: Arginase, secreted in the tumor microenvironment by myeloid suppressor cells, is a major regulator of arginine-mediated immune response. Arginase inhibition by INCB001158 increases arginine, which reverses the immunosuppressive effect
Autor:
Kees Bol, Fernando Bazan, Maria Vidal, Erika Hamilton, Viktoriya Stalbovskaya, François-Clément Bidard, Hans Wildiers, James M. Ford, Marie-Ange Mouret-Reynier, Joaquín Gavilá, Jean-Luc Re Canon, Florence Dalenc, Anthony Gonçalves, C. Murias, Sylvain Ladoire, Mohamed Bekradda, Ana Alexandra Ferreira, L. Andres Sirulnik, Anastasia Murat, Barbara Pistilli
Publikováno v:
Journal of Clinical Oncology. 38:1037-1037
1037 Background: MCLA-128 (zenocutuzumab) is an ADCC-enhanced humanized bispecific antibody targeting HER2 and HER3 and potently blocking HER3-ligand induced receptor dimerization. Upregulation of Her2:Her 3 pathway is a means of resistance to ET in
Autor:
Christophe Le Tourneau, Esma Saada-Bouzid, Catherine Fortpied, Carmela Caballero, Lisa Licitra, Jean-François Laes, Joël Guigay, Jean-Pascal Machiels, Jean-Luc Re Canon, Stéphanie Henry, Rachel Galot, Anne-Sophie Govaerts, Anthony Hee Kong, Tiana Raveloarivahy, Dominiek Staelens, Inge Tinhofer
Publikováno v:
Journal of Clinical Oncology. 36:TPS6095-TPS6095
TPS6095Background: The treatment of R/M SCCHN includes platinum-based chemotherapy, cetuximab, and anti-PD-1 compounds. Some genetic alterations have been identified, making SCCHN attractive for mo...
Autor:
Martine Berlière, Jean-Luc Re Canon, Christine Galant, François Duhoux, Isabelle Bar, Javier Carrasco, Paul Delrée, Pierre Coulie, David Schröder, Pascale Hilbert, Jean-Pascal Machiels
Publikováno v:
Journal of Clinical Oncology. 35:11554-11554
11554 Background: Breast carcinomas (BC) are often considered to be weakly immunogenic and thus poorly sensitive to immunotherapy. Methods: We analyzed the repertoire of tumor-infiltrating T cells (TILs) in 41 early BC by sequencing their T cell rece
Autor:
Meinolf Karthaus, Gianpiero Fasola, William Y. Go, J. Randolph Hecht, Hua Yu, Lee S. Schwartzberg, Fernando Rivera, Jean-Luc Re Canon, Kelly S. Oliner
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 32(21)
Purpose To evaluate panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated wild-type (WT) KRAS exon 2 (codons 12 and 13) metastatic colorectal cancer (mCRC). A
Autor:
Meinolf Karthaus, Jean-Luc Re Canon, Fernando Rivera, Reija Koukakis, Jan-Henrik Terwey, Lee S. Schwartzberg, Gianpiero Fasola, J. Randolph Hecht
Publikováno v:
Journal of Clinical Oncology. 33:660-660
660 Background: In the PEAK study, pmab + FOLFOX6 was associated with longer OS than bev + FOLFOX6 in first-line RAS WT mCRC. RECIST overall response rates (ORR) were similar between treatment arms. Here, we report exploratory analyses of tumour asse
Autor:
Jan-Henrik Terwey, Jean-Luc Re Canon, Jean-Yves Douillard, Reija Koukakis, David Cunningham, Fernando Rivera, Paul Ruff, Salvatore Siena, Josep Tabernero, György Bodoky
Publikováno v:
Journal of Clinical Oncology. 33:693-693
693 Background: The benefits of anti-cancer treatment must be balanced with the impact of adverse events on QoL. In the PRIME study, first-line pmab + FOLFOX4 significantly improved overall survival vs. FOLFOX4 in patients (pts) with RAS WT (KRAS/NRA
Autor:
Jean-Luc Re Canon, Jean-Charles Goeminne, Javier Carrasco, Lionel D'Hondt, Christine Sempoux, Thierry Delaunoit, Anne Jouret-Mourin, Jean-Pascal Machiels, Géraldine Pairet, Daniel Van Daele, Gauthier Demolin, Marie-Laure Castella, Gabriella Beniuga, Jean-Charles Coche, Ghislain Houbiers, Aline Van Maanen, Yves Humblet, Marc Van den Eynde
Publikováno v:
Journal of Clinical Oncology. 33:TPS795-TPS795
TPS795 Background: Even if the use of targeted therapies combined with chemotherapy has demonstrated increase response rate and survival benefit in non resectable metastatic colorectal cancer (mCRC), the administration of these combinations in frontl